Family Research Council Debunks Arguments for California bill to Mandate Abortion Pills in College Health Centers
WASHINGTON, May 21, 2019 /PRNewswire/ -- Last night, the California Senate passed Senate Bill 24, which would require the state's 34 public universities to dispense the abortion pill from their student health centers. Patrina Mosley, Family Research Council's Director of Life, Culture, and Women's Advocacy, debunked the arguments for this bill in her latest publication, "California's Campus Abortion Mandate is Bad Model Legislation."
The publication summarizes:
"This mandate shows a reckless disregard for the safety and health of young women and moreover creates considerable liability for the universities and all those involved, such as:
College dorm rooms are unsafe environments to have an abortion.
University student health centers (SHCs) are not equipped to handle adverse outcomes of on-campus abortions that may occur.
The bill's funding mechanism is purposefully vague.
No conscience exemptions are offered for college health center staff who may object to dispensing the abortion pill."
Family Research Council Director of Life, Culture, and Women's Advocacy Patrina Mosley added the following comments:
"The state of California is vying to be the first state in the nation that would force institutions of education to become abortion facilities--with no safeguards for protecting taxpayer dollars.
"Chemical abortions are traumatic multi-day processes that come with a risk of serious adverse effect. No dormitory community is prepared to handle the liabilities such a mandate creates. The physical and psychological health of women is at considerable risk, and no state should consider it for model legislation," concluded Mosley.
The Board of Directors of Revvity , today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024.
About Revvity ...
Edwards Lifesciences today reported financial results for the quarter ended March 31, 2024.
Highlights and Outlook
Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion
Q1 TAVR sales grew 6%; constant currency sales...
A functional assessment of Bacillus subtilis PLSSC (SEBtilistm) demonstrated its antimicrobial activity and capability to offer health benefits through industrial processing and the digestion process, showing its value-add in functional foods,...
Cronos Group Inc. ("Cronos" or the "Company") will hold its 2024 first quarter earnings conference call on Thursday, May 9, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today...
Stevanato Group S.p.A. , a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first...